Skip to main content

Healthy Volunteer Male Subjects

3
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Menarini
MenariniGermany - Dresden
1 program
1
TamsulosinPhase 11 trial
Active Trials
NCT07156916Recruiting46Est. May 2026
Berlin-Chemie
Berlin-ChemieGermany - Berlin
1 program
1
TamsulosinPhase 1
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
[11C]AZD1390Phase 11 trial
Active Trials
NCT03215381Completed8Est. Feb 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MenariniTamsulosin
AstraZeneca[11C]AZD1390

Clinical Trials (2)

Total enrollment: 54 patients across 2 trials

A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions

Start: Sep 2025Est. completion: May 202646 patients
Phase 1Recruiting

AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers

Start: Oct 2017Est. completion: Feb 20188 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 54 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.